We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tes... read more Featured Products: More products

Download Mobile App




Automated Multiplexing Molecular Diagnostic Platform Revolutionizes Infectious Disease Diagnostics

By LabMedica International staff writers
Posted on 06 Mar 2024

A new fully automated multiplexing molecular diagnostic platform offers an innovative and cost-effective testing approach by allowing customization of tests along with the ability to process and pay for desired results, thus enabling laboratories to maximize testing efficiencies. More...

Diasorin’s (Saluggia, Italy) new LIAISON PLEX platform provides complete flexibility for the customization of syndromic panels and helps overcome the challenge of the “one size fits all" approach faced by clinical laboratory staff for infectious disease syndromic diagnostics. Custom panels enable adjustments in response to seasonal changes and updates in clinical guidelines, helping prevent unnecessary and costly over-testing - a common issue with fixed, broad syndromic panels currently in use. The user-friendly, fully automated sample-to-answer system offers a streamlined workflow and room-temperature stable consumables, simplifying storage and transport logistics. Additionally, it requires just two minutes of hands-on time per sample and can deliver results in less than two hours.

The LIAISON PLEX, originally named VERIGENE II by Luminex, is VERIGENE’s successor, which is already providing flexible solutions with its Respiratory Panel. The PLEX system takes the Flex Testing concept to a new level with full customization of its existing and upcoming panels and full automation. This minimizes sample preparation time and contamination risks for laboratory technicians. The improved flexibility and automation add value for patients, clinicians, and payers. Given its unique features and technology, LIAISON PLEX is expected to boost Diasorin's commercial strategy in the U.S. by focusing on the hospital segment, leveraging IDNs, teaching institutions, and medical centers.

The LIAISON PLEX Respiratory Flex Assay is capable of testing for 19 pathogens linked to respiratory infections, which include 14 viral and 5 bacterial targets from nasopharyngeal swabs. The platform's Flex testing technology is unique in that it allows laboratories to select and pay for only specific results based on the patient's clinical symptoms, as opposed to standard panel tests that process all results simultaneously. This Flex approach enhances clinical utility and can lead to better reimbursement rates, making it a more cost-effective option for patients. The application of such targeted panel testing aids in precise diagnosis and treatment, aligning with the goals of diagnostic stewardship. This leads to reduced unnecessary patient therapies and avoids the costs associated with over-testing. The LIAISON PLEX platform, along with its Respiratory Flex Assay, has gained 510(k) clearance from the U.S. Food and Drug Administration (FDA).

“The LIAISON PLEX and its Respiratory Panel will allow clinical laboratories and physicians to tailor tests to the needs of their patient population,” said Angelo Rago, President of Luminex. “The LIAISON PLEX is truly a laboratory's sample-to-customizable answer solution and we believe this will help address the growing demand for diagnostic stewardship, fiscal responsibility, and operational efficiency in clinical labs and healthcare systems throughout the U.S.”

“The clearance of the LIAISON PLEX along with its first panel marks a significant and strategic milestone for Diasorin after the Luminex acquisition, delivering to the market an innovative platform that is uniquely positioned in the growing multiplexing industry” added Carlo Rosa, CEO of Diasorin. “The flex technology exemplifies our forward-looking approach to diagnostic development, tackling the current limitations of the multiplexing market with a fully automated and customizable panel, and providing customers with the needed flexibility to adopt this technology in a cost-effective manner.”


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Urine Drug Test
Instant-view® Phencyclidine Urine Drug Test
New
UHF RFID Tag & Inlay
AD-327 U9 ETSI Pure 95
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The POC device rapidly predicts neonatal respiratory disease at birth in the NICU (Photo courtesy of SIME Diagnostics)

AI-Powered Lung Maturity Test Identifies Newborns at Higher Risk of Respiratory Distress

Each year, approximately 300,000 babies in the United States are born between 32 and 36 weeks' gestation, according to national health data. This group is at an elevated risk for respiratory distress,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: This image shows a second-generation version of the device that can also measure cell morphology (Photo courtesy of MIT)

Rapid Cell Density Measurement Technique to Help Predict Immunotherapy Response

The density of a cell provides valuable insights into its condition. As cells go through processes such as proliferation, differentiation, or cell death, they may gain or lose water and other molecules,... Read more

Technology

view channel
Image: Scanning electron microscopy images showing 3D micro-printed Limacon-shaped whispering-gallery-mode microcavities with different amounts of deformation (Photo courtesy of A. Ping Zhang/PolyU)

Tiny Microlaser Sensors with Supercharged Biosensing Ability to Enable Early Disease Diagnosis

Optical whispering-gallery-mode microlaser sensors function by trapping light within tiny microcavities. When target molecules bind to the cavity, they induce subtle changes in the laser’s frequency, allowing... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.